Simple Summary ANCA-associated vasculitis (AAV) is a rare disease and manifests in
different organs. The exact mechanism of AAV is not fully understood, but it is speculated …

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells
and mature B cells (but not on plasma cells), was introduced in the late 1990s for the …

Objective B cell depletion with rituximab has allowed remissions in relapsing or refractory
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in small studies. The aim …

Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity
and not always effective. B lymphocytes have been implicated in the pathogenesis of …

Objective First, to investigate the overall efficacy and safety of rituximab (RTX) in refractory
granulomatosis with polyangiitis (GPA) in a tertiary referral centre. Second, to compare the …

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of …

Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells.
Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be …

Idiopathic membranous nephropathy is still the most common glomerular disease
associated with nephrotic syndrome. The greater the proteinuria, the greater the long-term …

Objective. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be
quite effective in the treatment of immune disorders resulting from autoantibodies. We …

Objectives. To perform a literature review and develop recommendations for the use of
rituximab in ANCA-associated vasculitis. Methods. A committee of experts (five …